Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
https://mobile.twitter.com/TimOilman/status/1358903554057076737
I think as well as the new Tier positions tomorrow, AZ will also be announced, Jusy my theory, stay well everyone.
https://www.omnia-health.com/product/pockit%E2%84%A2-central-nucleic-acid-analyzer
Jester, James told you that he will buy 29% of the company up to 20p...... after he has been voted in as CEO. He has not been voted in yet!
He will not buy any until then.
He has an order in place which will start after being made ceo, 29% to be bought within 1 month.
Lets wait for the results of the vote eh?
Long and strong .
Am I way off the mark here? Could James... Could he have sold 1% each day, to be bought by a series of people/companys? Would each holder be under the 3% notification? He has now sold 50% to.....? Only 10% to go, then buy another 29% @ under 20p. If this is what has really happenned ........ He would then hold 89% .....I must be going mad thinking along these lines. But if it came off, what a bargain!! Good luck all and stay well. Funny old world..eh?
Is my thinking correct, the only way the board can stop James buying 29% is to make the SP over 20p? I'm hoping for a lot higher and very soon. RNS tomorrow, we are all expecting shocking figures but hopefull that they are not too bad? Good luck all in your choices and stay well
And another
https://testingmethods.crowdicity.com/post/3167180
Thanks for sharing, this is getting interesting indeed.
https://testingmethods.crowdicity.com/post/3237330
Not sure if this has been posted .....
High Throughput SARS-CoV-2 PCR beads - Faster end to end testing, no reagent prep, high throughput stability
by
David Budd
David Budd
| 2 months ago | in Increasing end to end efficiency and speed of testing
C: Further assessment
Additional information
We have developed and manufactured a proprietary 1-step 96 well SARS-CoV-2 test. The Genedrive 96 SARS-CoV-2 test is presented as a fully complete, lyophilised PCR bead, arrayed across the wells of 96 well plate (high and low profile for various RT-PCR platforms), room temperature stable and suitable for high throughput workflows. There is no reagent preparation in the laboratory - saving all the reagent preparation time and personnel. This is a proprietary UK developed and manufactured product.
The test targets the E and N genes, has an internal RNA target assay control and an endogenous human RNA control in each of the 96 reactions. The product does not require refrigeration for storage.
Key efficiency improvements are:
1. There is no reagent preparation by the technicians in the lab, significantly saving time and labour, and reducing chances of test preparation error or variance.
2. The test available as an endpoint-PCR so it could be performed on a standard thermocycler, with just the last 10 minute reading phase done on an RT-PCR platform. This drastically reduces the need for RT-PCR equipment, and you can increase laboratory throughput with standard, comparatively less expensive PCR machines.
3. The test is UK manufactured and already established in facilities at high scale, starting at 10000 test beads per hour. Because a production batch of beads comes from a single preparation of liquid reagent, the tests are identical in concentration and composition of active ingredients across a 10000-100000+ test batch. There is no test variation, loss of stability, or variation from one testing site to another.
4. The beads are room temperature stable, supporting the longer term exposure required in high throughput workflows.
https://genedrive.com/assays/in-development-genedrive-96-sars-cov-2.php
Have you validated this method, if so, how and what were the results of the validation?
CE marking targeted w/c 18 May for full data set, but development performance sensitivity is at 5-10 copies of target per reaction. Further data with be available at the time of CE marking. We can share preliminary data with DHSC but we are not yet able to publish more details in this forum,
How quickly could this be deployed and what are the dependencies?
Targeting CE marked w/c 18 May, and available for manufacture and distribution thereafter. Potential volume dependencies on supply chain. Attached a photo showing the bead production in process.
What is the likely production volume??
Manufacturing capacity to several million t
https://health.economictimes.indiatimes.com/diagnostics-summit?utm_source=ethealthworld-com&utm_medium=banner-promotional-banner&utm_campaign=featured-4106-campaign-microsite-350
The Role of diagnostics in combating COVID-19 will be one of the topics
Could this be a help?